HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A massive block deal unfolded in the pharmaceutical sector as major institutional players shook up the equity structure of Corona Remedies Limited. High-profile investors, including HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA), stepped in to acquire significant stakes during this high-value transaction.
Details of the Massive Divestment
On June 17, 2026, a significant portion of the equity in Corona Remedies was offloaded through a coordinated block deal on the stock exchange. The primary seller, Sepia Investments, divested 43,28,943 shares at a price of ₹1,730 per share, amounting to approximately ₹748.9 crore.
Adding to the selling pressure, Anchor Partners also participated in the divestment, offloading 1,61,861 shares at the same price of ₹1,730 per share, worth roughly ₹28 crore. When combined, these two entities successfully exited positions worth a total of approximately ₹776.9 crore in the pharmaceutical company.
Institutional Heavyweights Drive the Buy Side
The transaction saw aggressive participation from twelve different institutional investors, signaling strong confidence in Corona Remedies' long-term prospects. HDFC Mutual Fund emerged as the dominant force on the buy side, acquiring 24,50,000 shares. This purchase, valued at roughly ₹423.9 crore, accounted for more than half of the total deal value.
Other prominent domestic and international players included:
- Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
- Aberdeen Asian Smaller Companies Investment Trust Plc: Acquired 4,50,868 shares for approximately ₹78 crore.
- Invesco Mutual Fund: Picked up 2,89,017 shares worth about ₹50 crore.
- Kotak Mahindra Mutual Fund: Bought 1,61,861 shares, mirroring the exact quantity sold by Anchor Partners, in a deal worth ₹28 crore.
Global and Specialized Funds Join the Fold
The deal attracted significant interest from global sovereign wealth funds and emerging market specialists. The Abu Dhabi Investment Authority (ADIA) entered the fray by purchasing 39,130 shares valued at ₹6.8 crore.
המערכת של WhiteOak וקרנות Aberdeen הראו גם הן תיאבון משמעותי. קרן Aberdeen Standard Sicav I - Asian Smaller Companies השקיעה כ-47.4 קרור רופי, בעוד שקרן WhiteOak Capital Mutual Fund וקרן Ashoka WhiteOak Emerging Markets Equity Fund רכשו אחזקות בשווי 25.1 קרור רופי ו-25.7 קרור רופי, בהתאמה. השתתפויות קטנות יותר בוצעו על ידי Factory Mutual Insurance Company וקרן TCW White Oak Emerging Markets Equity Fund, מה שהשלים קבוצה מגוונת של ספקי הון מתוחכמים ביותר.
נקודות מרכזיות
- יציאה משמעותית: Sepia Investments ו-Anchor Partners מכרו במצטבר מניות בשווי של כ-776.9 קרור רופי ב-Corona Remedies.
- דומיננטיות של HDFC MF: HDFC Mutual Fund היה הקונה הגדול ביותר, כשהוא סופג למעלה מ-50% משווי העסקה הכולל עם השקעה של 423.9 קרור רופי.
- ביטחון מוסדי: ההשתתפות של ענקיות גלובליות כמו ADIA וקרנות שונות של Aberdeen ו-WhiteOak מדגישה עניין מוסדי חזק בחברה במחיר של 1,730 רופי.